Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares US Real Estate ETF
IYR
|
+$947M |
| 2 |
Tesla
TSLA
|
+$608M |
| 3 |
Microsoft
MSFT
|
+$444M |
| 4 |
Accenture
ACN
|
+$409M |
| 5 |
iShares MSCI Emerging Markets ETF
EEM
|
+$396M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$2.06B |
| 2 |
Texas Instruments
TXN
|
+$1.92B |
| 3 |
Meta Platforms (Facebook)
META
|
+$1.81B |
| 4 |
Starbucks
SBUX
|
+$1.42B |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$1,000M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.52% |
| 2 | Financials | 7.13% |
| 3 | Consumer Discretionary | 6.46% |
| 4 | Healthcare | 5.43% |
| 5 | Communication Services | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4026
Organogenesis Holdings
ORGO
$305M
| $271K | ﹤0.01% |
94,809
+67,855
| +252% | +$190K |
|
4027
Solid Power
SLDP
$463M
| $271K | ﹤0.01% |
200,619
+146,157
| +268% | +$231K |
|
4028
Norwood Financial Corp
NWFL
$370M
| $270K | ﹤0.01% |
9,787
+7,215
| +281% | +$193K |
|
4029
Rackspace Technology
RXT
$1.05B
| $269K | ﹤0.01% |
109,997
+50,896
| +86% | +$123K |
|
4030
Contango Silver & Gold Inc
CTGO
$516M
| $269K | ﹤0.01% |
13,987
+11,028
| +373% | +$226K |
|
4031
Medifast
MED
$109M
| $269K | ﹤0.01% |
14,067
-1,275
| -8% | -$24.6K |
|
|
GRAL
4032
GRAIL Inc
GRAL
$2.94B
| $268K | ﹤0.01% |
19,476
-13,435
| -41% | -$204K |
|
|
API
4033
Agora
API
$338M
| $267K | ﹤0.01% |
110,848
-46,532
| -30% | -$103K |
|
4034
PCB Bancorp
PCB
$392M
| $265K | ﹤0.01% |
14,096
+10,565
| +299% | +$190K |
|
|
ESSA
4035
DELISTED
ESSA Bancorp
ESSA
| $264K | ﹤0.01% |
13,723
+8,895
| +184% | +$163K |
|
|
RAPP
4036
Rapport Therapeutics
RAPP
$1.96B
| $263K | ﹤0.01% |
12,863
+3,463
| +37% | +$74.4K |
|
4037
Algoma Steel
ASTL
$406M
| $263K | ﹤0.01% |
25,711
+15,305
| +147% | +$141K |
|
4038
U-Haul Holding Co
UHAL
$13.9B
| $263K | ﹤0.01% |
3,391
-41
| -1% | -$2.8K |
|
|
ZBIO
4039
Zenas BioPharma
ZBIO
$1.98B
| $262K | ﹤0.01% |
+15,500
| New | +$279K |
|
4040
Alico
ALCO
$280M
| $261K | ﹤0.01% |
9,336
+6,500
| +229% | +$180K |
|
4041
CALL
Kymera Therapeutics
KYMR
$8.51B
| $260K | ﹤0.01% |
+5,500
| New | +$243K |
|
4042
Zura Bio
ZURA
$516M
| $260K | ﹤0.01% |
64,061
+56,757
| +777% | +$212K |
|
4043
Alta Equipment Group
ALTG
$214M
| $258K | ﹤0.01% |
38,327
+28,812
| +303% | +$222K |
|
4044
BRC Group Holdings
RILY
$288M
| $258K | ﹤0.01% |
49,195
+37,241
| +312% | +$413K |
|
|
BRT
4045
BRT Apartments
BRT
$281M
| $258K | ﹤0.01% |
14,690
+10,973
| +295% | +$199K |
|
4046
Cellectar Biosciences
CLRB
$20.5M
| $258K | ﹤0.01% |
4,017
-1,723
| -30% | -$114K |
|
4047
LifeMD
LFMD
$169M
| $257K | ﹤0.01% |
49,017
+37,112
| +312% | +$214K |
|
4048
Lantronix
LTRX
$240M
| $257K | ﹤0.01% |
62,321
+43,770
| +236% | +$165K |
|
4049
BRC Inc
BRCC
$121M
| $256K | ﹤0.01% |
74,967
+57,366
| +326% | +$263K |
|
|
CTV
4050
DELISTED
Innovid Corp.
CTV
| $256K | ﹤0.01% |
142,422
+105,269
| +283% | +$191K |
|
Similar funds
Barclays's Q3 2024 Portfolio in Review
As of Q3 2024, Barclays held 5,593 positions worth $377B, up 15% from $327B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Barclays deployed $31.3B of net new capital in Q3 2024, opening 785 new positions and adding to 2,954 existing holdings. Its largest new stake was Smurfit Westrock: 3,460,710 shares worth $171M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was CRH, an estimated $2.06B trimmed.
- Barclays's largest Q3 2024 buy was Smurfit Westrock: 3,460,710 shares worth $171M.
- Barclays added most to iShares US Real Estate ETF in Q3 2024, an estimated $947M increase.
- Barclays's biggest Q3 2024 reduction was CRH, cutting an estimated $2.06B.
- Barclays fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $51.3M.
- Barclays's ten largest holdings make up 41% of its $377B portfolio in Q3 2024.
- Barclays opened 785 new positions and closed 322 in Q3 2024.
- Barclays's portfolio value rose 15% quarter-over-quarter to $377B.
Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.